| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Chapter Links... |
 Cancer Drugs Fund List |
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
Abemaciclib (Verzenios®)
(tablets)
|
Formulary
|
|
NICE TA563: abemaciclib for previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
|
Alectinib (Alecensa®)
|
Formulary
|
|
TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
|
Arsenic trioxide
(infusion)
|
Formulary
|
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
Atezolizumab
(infusion)
|
Formulary
|
|
NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment
|
Avelumab (Bavencio®)
(injection)
|
Formulary
|
Also available via MHRA EAMS (1 Sept 2020) for off label use in adults with advanced urothelial carcinoma that has not progressed after an initial course of chemotherapy.
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Bevacizumab (Avastin®)
(inj)
|
Formulary
|
For use in line with CDF criteria.
 Commissioned by NHS England for neurofibromatosis by NHS England as per national protocol (see NF2 service specification) at specialist centres only.
|
|
|
Blinatumomab
(injection)
|
Formulary
|
|
NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
|
Bortezomib
(injection)
|
Formulary
|
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
|
Brentuximab vedotin
(injection)
|
Formulary
|
|
NICE TA446 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
Carfilzomib
(Injection)
|
Formulary
|
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma
|
Cetuximab
(injection)
|
Formulary
|
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
Crisantaspase
(injection)
|
Formulary
|
|
|
|
Dacarbazine
(injection)
|
Formulary
|
|
|
|
Daratumumab (Darzalex®)
(infusion)
|
Formulary
|
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
|
Dinutuximab beta (Qarziba®)
(injection)
|
Formulary
|
|
NICE TA538: Dinutuximab beta for treating neuroblastoma
|
Durvalumab (Imfinzi®)
(injection)
|
Formulary
|
 NICE TA662: Durvalumab in combination for untreated extensive-stage small-cell lung cancer. Terminated appraisal as company withdrew evidence submission
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
|
Encorafenib (Braftovi®)
(capsules)
|
Formulary
|
|
NICE TA562: with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment
|
Entrectinib (Rozlytrek®)
(capsules)
|
Formulary
|
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
|
Eribulin
(injection)
|
Formulary
|
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Gemtuzumab ozogamicin (Mylotarg®)
(infusion)
|
Formulary
|
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
|
Gilteritinib (Xospata®)
(tablets)
|
Formulary
|
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Hydroxycarbamide
(capsule)
|
Formulary
|
|
|
|
Idelalisib
(tablet)
|
Formulary
|
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
|
Inotuzumab ozogamicin (Besponsa®)
(infusion)
|
Formulary
|
|
NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Ipilimumab
(injection)
|
Formulary
|
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
|
Isatuximab (Sarclisa®)
(Infusion)
|
Formulary
|
|
NICE TA658:Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
|
Ixazomib (Ninlaro®)
(capsule)
|
Formulary
|
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
|
Lenvatinib (Kisplyx®; Lenvima®)
(capsules)
|
Formulary
|
 Lenvima for thyroid and hepatocellular carcinoma, Kisplyx for renal cell carcinoma
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
|
Liposomal daunorubicin-cytarabine (Vyxeos®)
(infusion)
|
Formulary
|
|
NICE TA552: Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia
|
Lutetium (177Lu) oxodotreotride
(infusion)
|
Formulary
|
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
|
Midostaurin
(capsules)
|
Formulary
|
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia
|
Mitotane
(tablet)
|
Formulary
|
palliative use in adrenal carcinoma
|
|
|
Nivolumab (Opdivo®)
(infusion)
|
Formulary
|
For untreated advanced renal cell carcinoma: available through Cancer Drugs Fund, only if conditions in the managed access agreement are followed.
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA530:Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
|
Olaparib (Lynparza®)
(capsules/tablets)
|
Formulary
|
Note: NICE TA598 and TA620 only cover use of tablet formulation (not capsules)
Cancer Drugs Funding for 2nd line use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer (OLAP2) is under review and expected to be withdrawn March 2021 (see NICE GID-TA10712 and NHS England specialised commissioning circular SSC2225). Funding for use in 1st (OLAP1a and OLAP1b) and 3rd-line (OLAP3) settings will remain available.
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation.
|
Olaratumab
(injection)
|
Formulary
|
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
|
Panitumumab
(injection)
|
Formulary
|
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Panobinostat
(tablet)
|
Formulary
|
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pegaspargase (Oncaspar®)
(injection)
|
Formulary
|
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
|
Pembrolizumab (Keytruda®)
(injection)
|
Formulary
|
50mg powder for concentrate for solution for infusion is black triangle
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma - not recommended
Note: Funding from the Cancer Drugs Fund for 1st line use in urothelial cancer is under review and expected to be withdrawn Feb 2021 following publication of NICE terminated guidance (see GID-TA10710 and NHS England Specialised Commissioning circular SSC2223).
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA519:Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA557: Pembrolizumab for untreated, metastatic, non-squamous non-small-cell lung cancer, with pemetrexed and platinum chemotherapy
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
|
Pertuzumab
(infusion)
|
Formulary
|
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Polatuzumab vedotin (Polivy®)
(Injection)
|
Formulary
|
|
Polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B cell lymphoma
|
Streptozocin
(injection)
|
Formulary
|
 unlicensed
Locally advanced and metastatic neuroendocrine tumours
|
|
|
Talimogene laherparepvec (Imlygic®)
(injection)
|
Formulary
|
Observe special precautions for handling and disposal (refer to SPC section 6.6)
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
|
Temozolomide
(capsule)
|
Formulary
|
|
NHS England Clinical Commissioning Policy Ref 200203P: For treatment of newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (adults)
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
Trastuzumab
(injection)
|
Formulary
|
|
NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
|
Trastuzumab emtansine
(injection)
|
Formulary
|
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
|
Venetoclax (Venclyxto®)
(tablet)
|
Formulary
|
Venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if:
- there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and conditions for managed access agreement are followed.
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
(Injection)
|
Formulary
|
|
|
|
Cisplatin
(Injection)
|
Formulary
|
|
|
|
Oxaliplatin
(Injection)
|
Formulary
|
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
(capsule)
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
(tablet)
|
Formulary
|
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Axitinib
(tablet)
|
Formulary
|
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
|
Bosutinib
(tablet)
|
Formulary
|
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brigatinib (Alunbrig®)
(tablet)
|
Formulary
|
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
NICE TA670:Brigatinib for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (may be offered as an alternative to alectinib or crizotinib)
|
Cabozantinib (Cabometyx®)
(tablet)
|
Formulary
|
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516:Cabozantinib for treating medullary thyroid cancer
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Ceritinib
(capsule)
|
Formulary
|
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Crizotinib
(capsule)
|
Formulary
|
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Dacomitinib (Vizimpro®)
(film coated tablets)
|
Formulary
|
|
NICE TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Dasatinib
(tablet)
|
Formulary
|
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Erlotinib
(tablet)
|
Formulary
|
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Everolimus (Afinitor®)
(tablet)
|
Formulary
|
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus (Votubia®)
|
Formulary
|
For use as per commissioning criteria set by NHS England
|
|
|
Gefitinib
(tablet)
|
Formulary
|
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Ibrutinib (Imbruvica®)
(tablets)
|
Formulary
|
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA491:Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Imatinib
(tablet)
|
Formulary
|
|
NICE TA209:Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
|
Larotrectinib (Vitrakvi® )
(oral solution)
|
Formulary
|
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
|
Lorlatinib (Lorviqua®)
(tablet)
|
Formulary
|
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
|
Neratinib (Nerlynx®)
(tablets)
|
Formulary
|
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
|
Nilotinib
(capsule)
|
Formulary
|
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nintedanib
(capsule)
|
Formulary
|
Vargatef branf for NSCLC, Ofev brand for IPF in line with NICE guidance (see links)
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
|
Niraparib
(capsules)
|
Formulary
|
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
|
Osimertinib
(tablet)
|
Formulary
|
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Palbociclib (Ibrance®)
(capsules)
|
Formulary
|
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Pazopanib
(tablet)
|
Formulary
|
|
NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
|
Ponatinib
(tablet)
|
Formulary
|
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Regorafenib (Stivarga® )
(tablet)
|
Formulary
|
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Ribociclib (Kisqali®)
(tablets)
|
Formulary
|
|
NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Rucaparib (Rubraca®)
(tablets)
|
Formulary
|
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
|
Ruxolitinib (Jakavi®)
(tablet)
|
Formulary
|
Commissioned by NHSE in line with NICE TA and treatment criteria detailed in Cancer Drugs Fund list or on Blueteq application forms.
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Sorafenib
(tablet)
|
Formulary
|
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib
(capsule)
|
Formulary
|
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Tivozanib
(capsules)
|
Formulary
|
|
NICE TA512:Tivozanib for treating advanced renal cell carcinoma
|
Trametinib
(tablet)
|
Formulary
|
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Vemurafenib
(tablet)
|
Formulary
|
|
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
|
Dabrafenib
(capsule)
|
Formulary
|
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel
(injection)
|
Formulary
|
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel
(Injection)
|
Formulary
|
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
|
Paclitaxel
(Injection)
|
Formulary
|
|
NICE TA389:Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
|
Paclitaxel - Albumin Bound
(Injection)
|
Formulary
|
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan
(Injection)
|
Formulary
|
|
|
|
Topotecan
(injection/capsule)
|
Formulary
|
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin
(Injection)
|
Formulary
|
|
NICE TA185:Trabectedin for the treatment of advanced soft tissue sarcoma
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Tretinoin |
|
|
Tretinoin
(capsule)
|
Formulary
|
|
|
|
| .... |
| Non Formulary Items |
Alpelisib (Piqray®)
(tablets)
|
Non Formulary
|
|
NICE TA652: Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal).
|
Glasdegib (Daurismo®)
(tablets)
|
Non Formulary
|
|
NICE TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)
|
Lapatinib (Tyverb®)
|
Non Formulary
|
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
|
Necitumumab (Portrazza®)
|
Non Formulary
|
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
|
Pablociclib (Ibrance®)
|
Non Formulary
|
|
|
|
Ramucirumab (Cyramza®)
|
Non Formulary
|
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
|
Rociletinib
|
Non Formulary
|
|
|
|
Sonidegib (Odomzo®)
|
Non Formulary
|
|
|
|
Temsirolimus (Torisel®)
|
Non Formulary
|
|
NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
|
Vandetanib (Caprelsa®)
|
Non Formulary
|
|
|
|
Vosaroxin (Qinprezo)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Traffic Light Status Information
| Status |
Description |
|
Suitable for prescribing by all in both primary and secondary care. |
|
Specialist recommended but suitable for continuation in primary care. |
|
Specialist initiated but suitable for continuation in primary care. |
|
Specialist initiated and for continuation in primary care under a locally approved shared care guideline. |
|
Suitable for prescribing in specialist settings (secondary care) only. |
|
Secondary care medicines to be used under specialised commissioning arrangements only. |
|
For primary care, either via FP10 or supplied through specialist services. These products may be stocked by hospital
pharmacies only for supply to primary care units/wards or for continuing supplies for patients admitted on therapy. |
|
Not recommended for use. |
|
|
|
